Analysis device and analysis program
The analysis device uses PET-CT imaging to evaluate 5-FU accumulation ratios non-invasively, addressing the limitations of invasive tumor evaluations and improving drug efficacy assessments.
Patent Information
- Application Number
- JP2020178434
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-10-31
- Filing Date
- 2020-10-23
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2040-10-23
AI Technical Summary
Existing methods for evaluating the pharmacokinetics and drug efficacy of 5-FU are invasive and difficult to apply comprehensively due to the heterogeneity of tumors, placing a burden on patients and providing incomplete evaluations.
An analysis device that extracts and compares radioactivity values from tumor, blood, and muscle regions in nuclear medicine images to evaluate 5-FU accumulation using a PET-CT system, calculating ratios to determine drug efficacy without invasive procedures.
Enables non-invasive evaluation of 5-FU pharmacokinetics and efficacy, preventing ineffective treatments and side effects by assessing drug accumulation ratios, facilitating appropriate drug selection.
Smart Images

Figure 0007589935000001 
Figure 0007589935000002 
Figure 0007589935000003
Abstract
Description
[Technical field]
[0001] An embodiment of the present invention relates to an analysis device and an analysis program. [Background technology]
[0002] Conventionally, tests are performed to detect specific biological substances such as genes and proteins in order to select the appropriate anticancer drug for a patient. In particular, regarding the prediction of efficacy of the metabolic antagonist 5-FU (Fluorouracil), a relationship between the expression level of TS (Thymidylate synthase), an inhibitory target of 5-FU, and sensitivity to 5-FU has been reported, so it is said that the efficacy of 5-FU can be predicted to some extent by evaluating the expression level of TS in the pathological tissue of a patient.
[0003] However, in order to evaluate the expression level of TS, it is common to obtain pathological tissue from a patient by tissue biopsy and stain the obtained pathological tissue with a prescribed staining method, so the evaluation of the expression level of TS places a heavy burden on the patient due to its high invasiveness. Moreover, since tissue biopsy targets only a part of the tumor, it is difficult to evaluate the comprehensive pharmacokinetics and efficacy of 5-FU in tumors with heterogeneity by evaluating the expression level of TS. [Prior art documents] [Patent documents]
[0004] [Patent Document 1] JP 2015-044803 A [Non-patent literature]
[0005] [Non-Patent Document 1] Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L., Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors., Cancer Res. 1995 Apr 1;55(7):1407-12. [Non-Patent Document 2] Tsutani Y, Yoshida K, Sanada Y, Wada Y, Konishi K, Fukushima M, Okada M., Decrease orotate phosphoribosyltransferase activity produces 5-fluorouracil resistance in a human gastric cancer cell line., Oncol Rep. 2008 Dec;20(6):1545-51. Summary of the Invention [Problem to be solved by the invention]
[0006] The problem to be solved by the present invention is to enable evaluation of the comprehensive pharmacokinetics and efficacy of 5-FU without imposing a burden on patients. [Means for solving the problem]
[0007] The analysis device according to the embodiment includes an extraction unit, a calculation unit, and an evaluation unit. The extraction unit extracts detection values in a tumor region, a blood region, and a muscle region from a nuclear medicine image of a subject administered with a radioactively labeled anticancer drug that is effective by accumulating in a tumor. The calculation unit calculates a first comparison value that is a comparison result between the detection value in the blood region and the detection value in the tumor region, and a second comparison value that is a comparison result between the detection value in the muscle region and the detection value in the tumor region. The evaluation unit evaluates the accumulation of the drug in the tumor based on the first comparison value and the second comparison value calculated by the calculation unit. [Brief description of the drawings]
[0008] [Figure 1] FIG. 1 is a block diagram showing an example of the configuration of a medical image diagnostic system according to an embodiment. [Diagram 2] FIG. 2 is a flowchart illustrating an example of a flow of processing executed by the analysis device according to the embodiment. [Diagram 3] FIG. 3 shows the structural formula of [18F]5-FU. [Figure 4] FIG. 4 shows examples of PET images of DLD-1 mice and DLD-1 / 5-FU mice administered with [18F]5-FU. [Diagram 5] FIG. 5 is a diagram showing an example of an image obtained by superimposing a CT image and a PET image. [Figure 6] FIG. 6 is a graph showing the time course of accumulation of [18F] in tumors of DLD-1 mice and DLD-1 / 5-FU mice administered with [18F]5-FU. [Figure 7] FIG. 7 is a graph showing the tumor-blood ratios in DLD-1 mice and DLD-1 / 5-FU mice, calculated from the distribution of radioactivity in the tumor and blood. [Figure 8] FIG. 8 is a graph showing the tumor-muscle ratios in DLD-1 mice and DLD-1 / 5-FU mice, calculated from the distribution of radioactivity in the tumor and muscle. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0009] Hereinafter, an embodiment of an analysis device and an analysis program will be described in detail with reference to the drawings. Note that the embodiment is not limited to the following embodiment.
[0010] (Embodiment) The analysis device according to the embodiment includes an extraction unit, a calculation unit, and an evaluation unit. The extraction unit extracts detection values in a tumor region, a blood region, and a muscle region from a nuclear medicine image of a subject administered with a radioactively labeled anticancer drug that is effective by accumulating in a tumor. The calculation unit calculates a first comparison value that is a comparison result between the detection value in the blood region and the detection value in the tumor region, and a second comparison value that is a comparison result between the detection value in the muscle region and the detection value in the tumor region. The evaluation unit evaluates the accumulation of the drug in the tumor based on the first comparison value and the second comparison value calculated by the calculation unit. The first comparison value may be a ratio between the detection value in the blood region and the detection value in the tumor region. The second comparison value may be a ratio between the detection value in the muscle region and the detection value in the tumor region.
[0011] Fig. 1 is a block diagram showing an example of the configuration of a medical image diagnostic system according to an embodiment. As shown in Fig. 1, a medical image diagnostic system 10 according to an embodiment includes a medical image diagnostic device 100 and an analysis device 200. The medical image diagnostic device 100 and the analysis device 200 are communicatively connected via a network 300 such as an in-hospital LAN (Local Area Network).
[0012] In the following embodiment, a case will be described in which a PET-CT device in which a PET (Positron Emission computed Tomography) device and an X-ray CT (Computed Tomography) device are integrated is applied as the medical image diagnostic device 100, but the embodiment is not limited thereto, and for example, a PET device may be applied as the medical image diagnostic device 100. Furthermore, when a PET device is applied as the medical image diagnostic device 100, the medical image diagnostic system 10 may further include an X-ray CT device as a medical image diagnostic device separate from the medical image diagnostic device 100.
[0013] The medical image diagnostic device 100 is a device that captures medical images. The medical image diagnostic device 100 captures medical images depicting the inside of the body of a subject, and transmits the captured medical images to the analysis device 200. For example, the medical image diagnostic device 100 captures PET images depicting the inside of the body of a subject having a tumor, to which an anticancer drug 5-FU ([18F]5-FU) labeled with a positron-emitting nuclide 18F has been administered, and transmits the captured PET images to the analysis device 200. More specifically, the medical image diagnostic device 100 captures PET images of a subject having a tumor after a certain time has elapsed since administration of [18F]5-FU, and transmits the captured PET images to the analysis device 200. The medical image diagnostic device 100 also captures CT images depicting the inside of the body of a subject having a tumor, and transmits the captured CT images to the analysis device 200. A 5-FU degrading enzyme inhibitor may be administered to the subject together with [18F]5-FU. [18F]5-FU is an example of a radioactively labeled drug, 5-FU, an anticancer drug that is effective by accumulating in tumors. The subject may be one whose presence or absence of a tumor is unknown. PET images are an example of nuclear medicine images.
[0014] The analysis device 200 acquires medical images via the network 300 and executes various processes using the acquired medical images. For example, the analysis device 200 acquires PET images and CT images of a subject having a tumor to which [18F]5-FU has been administered via the network 300 and executes various processes using the acquired PET images and CT images. The analysis device 200 executes a processing function for enabling the comprehensive pharmacokinetics of 5-FU and the efficacy of 5-FU to be evaluated without imposing a burden on the patient. The analysis device 200 is realized by a computer device such as a workstation.
[0015] 1, the analysis device 200 includes a network interface 201, an input interface 202, a display 203, a memory circuit 204, and a processing circuit 205. The network interface 201, the input interface 202, the display 203, the memory circuit 204, and the processing circuit 205 are connected to each other.
[0016] The network interface 201 receives the medical image. The medical image received by the network interface 201 is stored in the memory circuitry 204.
[0017] The input interface 202 receives various input operations from an operator, converts the received input operations into electrical signals, and outputs the electrical signals to the processing circuit 205. For example, the input interface 202 is realized by a mouse, a keyboard, a trackball, a switch, a button, a joystick, a touchpad that performs input operations by touching the operation surface, a touch screen in which a display screen and a touchpad are integrated, a non-contact input circuit using an optical sensor, a voice input circuit, and the like. Note that the input interface 202 is not limited to only those that have physical operation parts such as a mouse and a keyboard. For example, an electrical signal processing circuit that receives an electrical signal corresponding to an input operation from an external input device provided separately from the analysis device 200 and outputs the electrical signal to the processing circuit 205 is also included as an example of the input interface 202.
[0018] The display 203 displays various information. For example, the display 203 displays medical images and the like under the control of the processing circuitry 205. The display 203 displays a GUI (Graphical User Interface) for receiving various instructions and various settings from an operator via the input interface 202. For example, the display 203 is a liquid crystal display or a CRT (Cathode Ray Tube) display. The display 203 may be a desktop type, or may be configured as a tablet terminal or the like capable of wireless communication with the main body of the analysis device 200. The display 203 is an example of a display unit.
[0019] The memory circuitry 204 is realized by, for example, a semiconductor memory element such as a random access memory (RAM) or a flash memory, a hard disk, an optical disk, or the like. The memory circuitry 204 is also used as a non-transient storage medium by hardware. The memory circuitry 204 stores acquired medical image data. Also, for example, the memory circuitry 204 stores a program for enabling a circuit included in the analysis device 200 to realize its function. The memory circuitry 204 is an example of a memory unit.
[0020] The processing circuitry 205 controls the overall processing of the analysis device 200. More specifically, the processing circuitry 205 has a display control function 205a, a reception function 205b, an extraction function 205c, a calculation function 205d, and an evaluation function 205e. The display control function 205a is an example of a display control unit. The reception function 205b is an example of a reception unit. The extraction function 205c is an example of an extraction unit. The calculation function 205d is an example of a calculation unit. The evaluation function 205e is an example of an evaluation unit.
[0021] Here, for example, each processing function of the processing circuit 205, that is, the display control function 205a, the reception function 205b, the extraction function 205c, the calculation function 205d, and the evaluation function 205e, is stored in the storage circuit 204 in the form of a program executable by a computer. The processing circuit 205 realizes the function corresponding to each program by reading each program from the storage circuit 204 and executing each program. In other words, the processing circuit 205 in the state in which each program is read has each function shown in the processing circuit 205 in FIG. 1. Note that, in FIG. 1, it has been described that each processing function of the display control function 205a, the reception function 205b, the extraction function 205c, the calculation function 205d, and the evaluation function 205e is realized by a single processing circuit 205, but the processing circuit 205 may be configured by combining a plurality of independent processors, and each processor may realize each processing function by executing each program.
[0022] The term "processor" used in the above description refers to circuits such as a CPU (Central Processing Unit), a GPU (Graphics Processing Unit), or an Application Specific Integrated Circuit (ASIC), a programmable logic device (e.g., a Simple Programmable Logic Device (SPLD), a Complex Programmable Logic Device (CPLD), and a Field Programmable Gate Array (FPGA)). Instead of storing a program in the memory circuit 204, the processor may be configured to directly incorporate the program into its circuit. In this case, the processor realizes its function by reading and executing the program incorporated in the circuit.
[0023] The display control function 205a causes various GUIs, medical images, etc. to be displayed on the display 203. For example, the display control function 205a causes the display 203 to display various GUIs, a PET image, a CT image, an overlaid image of a PET image and a CT image, etc.
[0024] The reception function 205b receives various operations by the operator via the input interface 202. For example, the reception function 205b receives an operation by the operator to set a region of interest within a tissue region via the input interface 202. More specifically, the reception function 205b receives an operation by the operator to set a region of interest within a tumor region, a heart region, and a muscle region via the input interface 202. The reception function 205b sends the received region of interest to the extraction function 205c. The heart region is an example of a blood region.
[0025] The extraction function 205c extracts radioactivity values in regions of interest set in the tissue region from a PET image of a subject having a tumor to which [18F]5-FU has been administered. For example, the extraction function 205c extracts radioactivity values (e.g., average radioactivity value, etc.) in a region of interest (tumor region of interest) set in the tumor region, a region of interest (heart region of interest) set in the heart region, and a region of interest (muscle region of interest) set in the muscle region from a PET image of a subject having a tumor to which [18F]5-FU has been administered. Note that the radioactivity values are an example of detection values.
[0026] The calculation function 205d calculates a first ratio, which is a ratio of the radioactivity value in the tumor region of interest to the radioactivity value in the heart region of interest, and a second ratio, which is a ratio of the radioactivity value in the tumor region of interest to the radioactivity value in the muscle region of interest, from the radioactivity values in the tumor region of interest, the heart region of interest, and the muscle region of interest extracted by the extraction function 205c. The first ratio is an example of a ratio of the detection value in the blood region to the detection value in the tumor region. The second ratio is an example of a ratio of the detection value in the muscle region to the detection value in the tumor region.
[0027] The evaluation function 205e evaluates the specificity of the accumulation of [18F]5-FU in the tumor from the first ratio and the second ratio calculated by the calculation function 205d. For example, the evaluation function 205e evaluates whether or not there is a tendency for [18F]5-FU to accumulate in the tumor by comparing the first ratio and the second ratio calculated by the calculation function 205d with a predetermined threshold (e.g., 1, etc.). The threshold may be set, for example, based on the first ratio and the second ratio obtained from a certain number of patients. In addition, evaluating the specificity from the first ratio and the second ratio is an example of evaluating the accumulation of the drug in the tumor based on the ratio of the detection value in the blood region to the detection value in the tumor region and the ratio of the detection value in the muscle region to the detection value in the tumor region.
[0028] Next, an example of the flow of the process executed by the analysis device 200 according to the embodiment will be described. Fig. 2 is a flowchart showing an example of the flow of the process executed by the analysis device 200 according to the embodiment. Note that this description is based on the premise that a PET image and a CT image obtained by administering [18F]5-FU to a subject having a tumor and imaging the subject after a certain time has elapsed from the administration by the medical image diagnostic device 100 are stored in the memory circuitry 204 in advance.
[0029] First, the display control function 205a causes the display 203 to display the CT image stored in the memory circuitry 204 (S1). The display control function 205a may also cause the display 203 to display a superimposed image of the PET image and the CT image.
[0030] The operator confirms the positions of the subject's tumor, heart as a blood pool, and muscles from the CT image displayed on the display 203. The operator performs an operation to set a region of interest within the tumor region, heart region, and muscle region in the image via the input interface 202. When a superimposed image is displayed on the display 203, the operator confirms the positions of the subject's tumor, heart as a blood pool, and muscles from the superimposed image, and performs an operation to set a region of interest within the tumor region, heart region, and muscle region in the image.
[0031] Next, the reception function 205b receives the setting of regions of interest within the tumor region, heart region, and muscle region by the operator, and sends the received settings of the regions of interest (tumor region of interest, heart region of interest, and muscle region of interest) to the extraction function 205c (S2).
[0032] Here, the setting of the region of interest is not limited to being performed manually, but may be performed automatically. For example, the contour of a structure in an image may be extracted by a known segmentation process, and the region of interest may be set in the image based on the position and shape of the extracted contour.
[0033] Next, the extraction function 205c extracts the average radioactivity values within the set tumor region of interest, heart region of interest, and muscle region of interest from the PET image (S3).
[0034] Next, calculation function 205d calculates a first ratio, which is the ratio of the average radioactivity in the tumor region of interest to the average radioactivity in the heart region of interest, and a second ratio, which is the ratio of the average radioactivity in the tumor region of interest to the average radioactivity in the muscle region of interest, from the average radioactivity values in the extracted tumor region of interest, heart region of interest, and muscle region of interest (S4).
[0035] Next, the evaluation function 205e evaluates that the tumor has a tendency for [18F]5-FU to accumulate if both the calculated first ratio and second ratio are greater than a predetermined threshold, and evaluates that the tumor has no tendency for [18F]5-FU to accumulate if at least one of the calculated first ratio and second ratio is smaller than a predetermined threshold (S5). Note that the evaluation function 205e may evaluate that the tumor has a moderate tendency for [18F]5-FU to accumulate if either one of the first ratio and the second ratio is smaller than a predetermined threshold, and evaluate that the tumor has no tendency for [18F]5-FU to accumulate if both the first ratio and the second ratio are smaller than a predetermined threshold.
[0036] Then, a doctor can refer to the evaluation results obtained by analysis device 200 to determine whether to apply a treatment using 5-FU or a treatment other than 5-FU to the subject being evaluated.
[0037] In this manner, in the embodiment, a first ratio, which is the ratio of the radioactivity value in the tumor region to the radioactivity value in the heart region, and a second ratio, which is the ratio of the radioactivity value in the tumor region to the radioactivity value in the muscle region, are calculated from the radioactivity values in the tumor region, heart region, and muscle region extracted from a PET image of a subject having a tumor to which [18F]5-FU has been administered, and the specificity of the accumulation of [18F]5-FU in the tumor is evaluated from the calculated first ratio and second ratio. Therefore, according to the embodiment, the comprehensive pharmacokinetics of 5-FU and the efficacy of 5-FU can be evaluated without imposing a burden on the patient.
[0038] More specifically, according to the embodiment, the accumulation of 5-FU in a tumor can be evaluated without placing a burden on the patient. Also, according to the embodiment, it is possible to prevent administration to patients who are not expected to benefit from 5-FU treatment, and thus the occurrence of side effects can be prevented. Also, according to the embodiment, it is possible to easily evaluate changes in the pharmacokinetics of 5-FU caused by the acquisition of resistance to 5-FU due to continuous administration of 5-FU. Also, according to the embodiment, it is possible to prevent the progression of cancer associated with continuous administration of 5-FU to patients who are not expected to benefit from 5-FU treatment. Also, according to the embodiment, it is possible to contribute to the judgment of switching to an appropriate anticancer drug.
[0039] Although an embodiment of the present invention has been described, this embodiment is presented as an example and is not intended to limit the scope of the invention. This embodiment can be implemented in various other forms, and various omissions, substitutions, and modifications can be made without departing from the gist of the invention. This embodiment and its modifications are included in the scope of the invention and its equivalents described in the claims, as well as in the scope and gist of the invention. EXAMPLES
[0040] (Example 1) Visualization of the pharmacokinetics of 5-FU using [18F]5-FU We attempted to visualize the pharmacokinetics of 5-FU using [18F]5-FU by performing the following experiments 11 to 15 on DLD-1 mice (N = 8) and DLD-1 / 5-FU mice (N = 8).
[0041] Here, DLD-1 mice were immunized with tumors derived from the DLD-1 colon cancer cell line (mean tumor volume 107 mm 3 The DLD-1 / 5-FU mice were tumor-bearing mice with tumors derived from the colon cancer cell line DLD-1 / 5-FU (mean tumor volume 86 mm 3 ) tumor-bearing mice. DLD-1 / 5-FU was established by culturing DLD-1 in a medium containing 5-FU. DLD-1 and DLD-1 / 5-FU have different sensitivities to 5-FU, with DLD-1 being sensitive to 5-FU and DLD-1 / 5-FU being resistant to 5-FU.
[0042] [Step 11] 18MBq of [18F]5-FU (see Figure 3) and 10mg / kg of gimeracil (5-FU degrading enzyme inhibitor) are simultaneously administered to each mouse via tail vein injection. Note that a dose of 18MBq of [18F]5-FU corresponds to a dose of 1.5pg / kg of 5-FU.
[0043] [Step 12] Approximately 45 minutes after administration, the mouse is anesthetized and fixed to the imaging stage.
[0044] [Step 13] 50 minutes after administration, the mouse is imaged for 10 minutes using a static scan with a PET device (Canon Medical Systems Corporation).
[0045] [Step 14] After imaging with the PET device, the imaging stage on which the mouse is fixed is moved to an X-ray CT device (manufactured by Canon Medical Systems Corporation), and the mouse is imaged with the X-ray CT device.
[0046] [Step 15] PET imaging is performed using a medical image analysis viewer (software) that is installed in a computer connected to the PET and X-ray CT scanners and that can set the region of interest and extract the average radioactivity value (%ID / g and SUV (Standardized Uptake Value)) within the region of interest. Specifically, the mouse weight, the dose of [18F]5-FU, the administration time, and the imaging start time are input on a specific operation screen provided by the viewer and displayed on the computer display, and the image contrast is set to the range of 0.5 to 2.0%ID / g wt, and PET imaging is performed.
[0047] An example of a PET image obtained by the experiment is shown in FIG. 4. The image shown in FIG. 4(a) is a PET image of a DLD-1 mouse, and the image shown in FIG. 4(b) is a PET image of a DLD-1 / 5-FU mouse. In the figure, the circled area corresponds to the tumor area. The PET images allowed visualization of a clear difference in the amount of [18F] accumulation between the DLD-1-derived tumor and the DLD-1 / 5-FU-derived tumor.
[0048] (Example 2) Evaluation of specificity of accumulation of [18F]5-FU in tumors In Example 1, PET images confirmed the accumulation of [18F] only in the tumor derived from DLD-1.
[0049] However, the amount of [18F] retained in the whole body of a mouse may vary between individuals. For example, in mice with high accumulation of [18F] in the whole body, the tumor may be highlighted in the PET image, making it impossible to determine whether or not there is specific accumulation of [18F] in the tumor. Conversely, in mice with low accumulation of [18F] in the whole body, it is impossible to determine whether there is no accumulation of [18F] in the tumor or whether the absolute amount of accumulation of [18F] is so small that it is not highlighted in the PET image.
[0050] Therefore, it is considered necessary to quantify the radioactivity at the tumor site from PET images and compare the quantified radioactivity between individuals.
[0051] However, because the amount of radioactivity retained throughout the body differs from individual to individual, it is not appropriate to compare only the radioactivity accumulated in the tumors between individuals.
[0052] Therefore, in Example 2, the ratio of radioactivity in the tumor to the radioactivity in the heart (hereinafter referred to as the "tumor-blood ratio") and the ratio of radioactivity in the tumor to the radioactivity in the muscle (hereinafter referred to as the "tumor-muscle ratio") were calculated using the radioactivity in the heart as the blood pool and the muscle as the standard, and the calculated tumor-blood ratios and tumor-muscle ratios were compared between individuals to relatively evaluate the specificity of [18F] accumulation in the tumor.
[0053] The tumor-blood ratio and tumor-muscle ratio of each mouse used in Example 1 were calculated according to steps 21 to 24 below, and from the calculated tumor-blood ratio and tumor-muscle ratio of each mouse, the average tumor-blood ratio and average tumor-muscle ratio of DLD-1 mice and the average tumor-blood ratio and average tumor-muscle ratio of DLD-1 / 5-FU mice were calculated.
[0054] [Step 21] Use the viewer to generate a superimposed image of the mouse's PET and CT images.
[0055] [Step 22] While observing the superimposed image (see Figure 5), distinguish between the tumor, heart, and muscle regions.
[0056] [Step 23] On a specific operation screen provided by the viewer, a region of interest is set within each of the identified regions, and the average radioactivity value within each region of interest is extracted using the viewer.
[0057] [Step 24] Calculate the tumor-blood ratio and tumor-muscle ratio from the average radioactivity within each extracted region of interest.
[0058] The specificity of tumor accumulation was evaluated from the calculated average tumor-blood ratio and average tumor-muscle ratio in DLD-1 and DLD-1 / 5-FU mice. The average tumor-blood ratio was 1.07 in DLD-1 / 5-FU mice, whereas the average tumor-muscle ratio was 1.99 in DLD-1 mice, which was significantly higher (p<0.01). The average tumor-muscle ratio was 2.14 in DLD-1 mice, whereas the average tumor-blood ratio was 1.08 in DLD-1 / 5-FU mice, which was significantly higher (p<0.01). In other words, the average tumor-blood ratio in DLD-1 mice was approximately 1.86 times higher than that in DLD-1 / 5-FU mice, and the average tumor-muscle ratio was approximately 1.98 times higher than that in DLD-1 / 5-FU mice, both of which were significantly higher.
[0059] Furthermore, to verify the validity of the comparison results of the tumor-blood ratio and tumor-muscle ratio obtained from the PET images, the radioactivity value, tumor-blood ratio, and tumor-muscle ratio of the tumor obtained from the tissue obtained by dissection were compared. Specifically, four DLD-1 mice and four DLD-1 / 5-FU mice were prepared at each time point of 10 minutes, 30 minutes, 60 minutes, and 240 minutes after administration, and the following experiments of steps 31 to 34 were performed for each mouse to quantitatively compare the tumor radioactivity value between DLD-1 mice and DLD-1 / 5-FU mice, as well as the tumor-blood ratio and tumor-muscle ratio between DLD-1 mice and DLD-1 / 5-FU mice. In addition, when obtaining the tumor-blood ratio from the tissue obtained by dissection, the radioactivity in the blood actually collected was used as the standard, not the radioactivity in the heart, so the tumor-blood ratio obtained from the tissue obtained by dissection is the ratio of the radioactivity in the tumor to the radioactivity in the blood.
[0060] [Procedure 31] Mice are simultaneously administered 1.8 MBq of [18F]5-FU per mouse and 10 mg / kg of gimeracil per mouse via tail vein injection.
[0061] [Step 32] After the time points have passed, dissect the mice promptly and analyze the distribution of radioactivity in each tissue (tumor, blood, muscle, lung, bone, etc.). Specifically, dissect the mice, separate each tissue from the mice, and promptly measure the weight of each separated tissue and the radioactivity level contained in each separated tissue.
[0062] [Step 33] Calculate the radioactivity per unit weight of each tissue from the measured weight of each tissue and the radioactivity contained in each tissue.
[0063] [Step 34] Calculate the tumor-blood ratio and tumor-muscle ratio from the calculated tumor radioactivity levels, blood radioactivity levels, and muscle radioactivity levels.
[0064] As a result of the comparison, in DLD-1 mice, the average accumulation of [18F] (%ID / g) was 2.0 times higher (see the point corresponding to 60 minutes after administration in the line graph shown in Figure 6), the average tumor-blood ratio was 1.6 times higher (see the bar graph corresponding to the notation "60 min" in Figure 7), and the average tumor-muscle ratio was 1.9 times higher (see the bar graph corresponding to the notation "60 min" in Figure 7) compared to DLD-1 / 5-FU mice, all of which were significantly higher (p<0.01).
[0065] As shown in Figure 6, the accumulation in DLD-1 mice was higher than that in DLD-1 / 5-FU mice at 10, 30, and 240 minutes after administration. More specifically, the accumulation in DLD-1 mice was not significantly different from that in DLD-1 / 5-FU mice at 10 and 240 minutes after administration, but the accumulation in DLD-1 mice was significantly higher than that in DLD-1 / 5-FU mice at 30 minutes after administration (p<0.01). In addition, as shown in Figures 7 and 8, the tumor-blood ratio and tumor-muscle ratio in DLD-1 mice were higher than those in DLD-1 / 5-FU mice at 10, 30, and 240 minutes after administration. More specifically, 10 minutes and 240 minutes after administration, the tumor-blood ratio and tumor-muscle ratio of DLD-1 mice were not significantly different from those of DLD-1 / 5-FU mice, but 30 minutes after administration, the tumor-blood ratio and tumor-muscle ratio of DLD-1 mice were significantly higher than those of DLD-1 / 5-FU mice (p<0.01).
[0066] In Examples 1 and 2, a correlation was observed between the results of comparing the distribution of radioactivity in tissues obtained from PET images and the actual distribution of radioactivity in tissues in the body, and it was therefore demonstrated that visualization of the pharmacokinetics of 5-FU using [18F]5-FU and evaluation of the specificity of accumulation of [18F]5-FU in tumors are possible in mice. [Explanation of symbols]
[0067] 10 Medical imaging diagnostic systems 100 Medical imaging diagnostic equipment 200 Analysis equipment 201 Network Interface 202 Input Interface 203 Display 204 Memory circuit 205 Processing Circuit 205a Display control function 205b Reception function 205c extraction function 205d Calculation Function 205e Evaluation Function 300 Network
Claims
1. An acquisition unit for acquiring CT images and nuclear medicine images of a subject administered with a radioactively labeled anticancer drug that is effective by accumulating in a tumor; a receiving unit that receives a setting of a region of interest that specifies a tumor region, a blood region, and a muscle region based on the CT image; an extracting unit that extracts detection values in a tumor region, a blood region, and a muscle region from the nuclear medicine image based on the set region of interest; a calculation unit that calculates a first comparison value that is a comparison result between the detection value in the blood region and the detection value in the tumor region, and a second comparison value that is a comparison result between the detection value in the muscle region and the detection value in the tumor region; an evaluation unit that performs a first determination as to whether or not a condition related to the first comparison value is satisfied, and performs a second determination as to whether or not a condition related to the second comparison value is satisfied, and evaluates the accumulation of the drug in a tumor based on a combination of the first determination and the second determination; An analysis device comprising:
2. The analysis device according to claim 1 , wherein the first comparison value is a ratio of the detection value in the blood region to the detection value in the tumor region.
3. The analysis device according to claim 1 , wherein the second comparison value is a ratio of the detection value in the muscle region to the detection value in the tumor region.
4. On the computer, An acquisition function for acquiring CT images and nuclear medicine images of a subject to which a radioactively labeled anticancer drug that is effective by accumulating in a tumor has been administered; A reception function for receiving settings of a region of interest that specifies a tumor region, a blood region, and a muscle region based on the CT image; an extraction function for extracting detection values in a tumor region, a blood region, and a muscle region from the nuclear medicine image based on the set region of interest; a calculation function for calculating a first comparison value which is a comparison result between the detection value in the blood region and the detection value in the tumor region, and a second comparison value which is a comparison result between the detection value in the muscle region and the detection value in the tumor region; an evaluation function of making a first determination as to whether or not a condition related to the first comparison value is satisfied, and making a second determination as to whether or not a condition related to the second comparison value is satisfied, and evaluating the accumulation of the drug in the tumor based on a combination of the first determination and the second determination; An analysis program to achieve this.
5. An analytical device described in any one of claims 1 to 3, wherein the evaluation unit evaluates the accumulation of the drug in the tumor in three or more stages based on a combination of the first judgment and the second judgment.
6. An analysis device as described in any one of claims 1 to 3 and 5, wherein the reception unit receives an operation from an operator to set the region of interest in a superimposed image of the CT image and the nuclear medicine image displayed on the display unit.
7. The reception unit accepts the setting of the region of interest based on a segmentation process for the CT image. The analysis device according to any one of claims 1 to 3 and 5.
Citation Information
Patent Citations
Diagnostic imaging agent, antitumor effect prediction device, antitumor agent effect prediction method and antitumor effect prediction program
JP2015044803A
Uses of labeled HSP90 inhibitors
JP2017121233A
Compounds and Compositions for Imaging GCC-Expressing Cells
JP2017503763A
